|Videos|March 10, 2022
- Dermatology Times, April 2022 (Vol. 43. No. 4)
- Volume 43
- Issue 4
- Pages: 23
Drug Watch: What's Coming in the Rosacea Pipeline
Author(s)Linda Stocum, Associate Editor
Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, who dives into what is currently lacking is rosacea patient care, how the new mechanisms of action of these potential treatments will better address current struggles, and more.
Advertisement
Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, chair of dermatology at the University of California-San Diego, in San Diego, California, about what's happening in the rosacea drug pipeline. In this video interview, Gallo talks about what's new in treatment, how certain rosacea phenotypes are harder to treat than others, and what is being done to addresss these issues.
Articles in this issue
over 3 years ago
Microneedling Misconceptionsover 3 years ago
2022: Meeting the Challenges of Advanced BCCover 3 years ago
Cost of Copies Prompts a Lawsuitover 3 years ago
Diverse Perspectives in Medical Aesthetics Matter More Than Everover 3 years ago
Cellular Grafting in Vitiligoover 3 years ago
Polish Skills to Treat Nail Disordersover 3 years ago
Identifying Diagnostic Bias in Skin of Colorover 3 years ago
Machine Learning to Identify Biomarkers in ADover 3 years ago
Effect of Joint Pain on Analgesic Use in Patients with PsoriasisNewsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata
5
